24-Hour Crisis Hotline: (877)SAFEGBC or (877)723-3422 Mental Health & Substance Abuse Issues

6502 Nursery Drive, Suite 100
Victoria, TX 77904
(361)575-0611
(800)421-8825

Medical Disorders
Resources
Basic InformationLookupsLatest News
Heading to Europe This Summer? Get Your Measles ShotAiling Heart Can Speed the Brain's Decline, Study FindsHealth Tip: Preventing GlaucomaHead Injuries Tied to Motorized Scooters Are Rising: StudyOverweight Kids Are at Risk for High Blood PressureHot Water Soak May Help Ease Poor Leg CirculationHealth Tip: Understanding RosaceaHealth Tip: Causes of Swollen Lymph NodesAHA News: Study Provides Rare Look at Stroke Risk, Survival Among American IndiansCDC Opens Emergency Operations Center for Congo Ebola OutbreakScared Safe: Pics of Sun's Damage to Face Boost Sunscreen UseNo Needle Prick: Laser-Based Test Hunts Stray Melanoma Cells in BloodBats Are Biggest Rabies Danger, CDC SaysEmgality Receives First FDA Approval for Treating Cluster HeadacheZerbaxa Approved for Hospital-Acquired Bacterial PneumoniaBlood From Previously Pregnant Women Is Safe for Donation: StudyStudy Refutes Notion That People on Warfarin Shouldn't Eat Leafy GreensCancer Survivors Predicted to Top 22 Million by 2030Your Guide to a Healthier Home for Better Asthma ControlHigh Blood Pressure at Doctor's Office May Be More Dangerous Than SuspectedAHA News: 3 Simple Steps Could Save 94 Million Lives WorldwideHealth Tip: Dealing With Motion SicknessHealth Tip: Symptoms of MeningitisRace Affects Life Expectancy in Major U.S. CitiesVitamin D Supplements Don't Prevent Type 2 Diabetes: StudyChickenpox Vaccine Shields Kids From Shingles, TooWhooping Cough Vaccine Effectiveness Fades With Time: StudyOpioids Put Alzheimer's Patients at Risk of Pneumonia: StudyHealth Tip: Early Signs of Lyme DiseaseHealth Tip: Hiccup Home RemediesSheep Study Shows a Stuffy Side Effect of VapingShould Air Quality Checks Be Part of Your Travel Planning?Health Tip: Preventing Swimmer's EarHeartburn Drugs Again Tied to Fatal RisksHealth Tip: Nasal Spray SafetyFDA Approves First Drug to Help Tame Cluster HeadachesMany Dietary Supplements Dangerous for TeensAverage American Ingests 70,000 Bits of Microplastic Each YearFalls Are Increasingly Lethal for Older AmericansChicken No Better Than Beef for Your Cholesterol?Another Use for Beta Blockers? Curbing A-fibCaffeine, Nicotine Withdrawal Can Cause Problems in the ICU: StudyYounger Gout Patients Have Higher Odds for Blood ClotsFDA Approves First Test for Zika in Human BloodCDC Warns Again of Salmonella From Pet HedgehogsWhy Some Kids With Eczema Are at Higher Allergy RiskMany Heart Failure Patients Might Safely Reduce Use of DiureticsU.S. Measles Cases for 2019 Already Exceed All Annual Totals Since 1992: CDCForget Fasting Before That Cholesterol TestU.S. Cancer Cases, Deaths Continue to Fall
Questions and AnswersLinks
Related Topics

Diabetes

New Antibiotic Treats Pneumonia, Skin Infections

HealthDay News
by By Amy NortonHealthDay Reporter
Updated: Feb 6th 2019

new article illustration

WEDNESDAY, Feb. 6, 2019 (HealthDay News) -- An updated version of an old antibiotic works well against pneumonia and serious skin infections -- giving doctors a new option for some common ills, researchers say.

In two trials, researchers found that the drug -- called omadacycline -- worked as well as standard antibiotics in treating patients with "community-acquired" pneumonia or skin infections.

That means they got sick out in the real world, rather than developing the infections while in the hospital -- which are typically more severe.

The U.S. Food and Drug Administration approved omadacycline in October, when the agency reviewed the trial findings. The results are now being published in the Feb. 7 issue of the New England Journal of Medicine.

The drug is a revamped, "modernized" tetracycline, explained senior researcher Dr. Evan Loh, president of Paratek Pharmaceuticals, the Boston-based maker of omadacycline.

Tetracyclines have been around for decades, and during that time bacteria have developed ways to resist the drugs. It's one example of the wider problem of antibiotic resistance -- where long-used drugs are starting to lose their effectiveness against various bacterial infections.

Omadacycline was designed to thwart the two major mechanisms that bacteria use to evade tetracyclines, Loh explained.

In both of the new trials, his team found that omadacycline was as effective as the standard antibiotics linezolid and moxifloxacin.

In a nutshell, that means the drug "worked pretty well," said Dr. Henry Chambers, an infectious disease specialist at the University of California, San Francisco.

But Chambers, who wrote an editorial published with the studies, questioned how valuable that will ultimately be.

That's because doctors already have "pretty good options" for the infections treated in these trials, he said.

The biggest scourge, Chambers said, are those cases of pneumonia and other serious infections that are resistant to multiple existing antibiotics.

"That's where the real medical need is," he said.

Each year in the United States, at least 2 million people develop antibiotic-resistant infections, and upwards of 23,000 die, according to the U.S. Centers for Disease Control and Prevention.

One way to combat the problem is by developing new antibiotics that work through novel mechanisms, Chambers said. Alternatively, researchers can tweak existing drugs to overcome the methods bacteria used to render themselves treatment-resistant.

Omadacycline falls into that latter category.

One of the new trials focused on patients who had to be hospitalized after developing bacterial pneumonia. Loh's team randomly assigned 386 to treatment with omadacycline; another 388 were assigned to moxifloxacin. Both antibiotics were first given by IV once a day. After three days, patients could switch to pills.

Overall, 81 percent of omadacycline patients had an "early clinical response." That meant at least two of their symptoms -- such as chest pain, coughing and breathing problems -- improved significantly within three to five days.

That rate was just under 83 percent of patients on the standard antibiotic.

As for side effects, gastrointestinal woes -- nausea, vomiting and diarrhea -- were the most common issue with either antibiotic.

The effectiveness was similar in the second trial, of more than 600 patients with severe skin infections. Half were assigned to omadacycline, half to linezolid -- and the rates of early clinical response were about 85 percent in both groups.

Speaking to Chambers' point, Loh said that the new antibiotic is aimed at the type of patient who becomes sick out in the real world -- not the seriously ill hospital patient whose infection may resist the gamut of antibiotics.

"We're not the drug for that," Loh said.

On the other hand, he pointed out, there are reasons why certain patients cannot take the existing antibiotics: Some have conditions that put them at risk of rare, serious side effects, for example, while others are on medications that interact with the current drugs.

Omadacycline is another option, according to Loh.

He and Chambers also made this bigger point: No matter how many new antibiotics are created, the importance of "judicious" antibiotic use will never dim.

It's estimated that around half of antibiotic prescriptions in the United States are inappropriate, Chambers said.

"Inappropriate use has certainly been a big contributor to the problem we face now," he said.

More information

The U.S. Centers for Disease Control and Prevention has more on antibiotic resistance.